TLR7 was also found to be positively related to certain well‐recognized immune checkpoints (e.g., PDCD1, CD247, PDCD1LG2, CTLA4, HAVCR2, and IDO1) (r > 0.45, p < 0.001), which revealed that TLR7 might play a potential role in the response to immunotherapy in STAD (Figure 7B). This evidence concerns the gene PDCD1LG2 and gastric adenocarcinoma.